$7.04
0.08[1.15%]
Last update: 10:54AM Get Real Time Here
Actinium Pharma
(AMEX:ATNM)Actinium Pharma Stock (AMEX:ATNM), Analyst Ratings, Price Targets, Predictions
Actinium Pharmaceuticals Inc has a consensus price target of $24.8, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on April 1, 2024, April 1, 2024, and March 26, 2024. With an average price target of $40.33 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 472.92% upside for Actinium Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Maxim Group
B. Riley Securities
HSBC
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Actinium Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | ATNM | Buy Now | Actinium Pharma | $7.04 | 610.23% | HC Wainwright & Co. | Joseph Pantginis | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | ATNM | Buy Now | Actinium Pharma | $7.04 | 198.3% | Cantor Fitzgerald | Kristen Kluska | → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2024 | ATNM | Buy Now | Actinium Pharma | $7.04 | 610.23% | HC Wainwright & Co. | Joseph Pantginis | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | ATNM | Buy Now | Actinium Pharma | $7.04 | 326.14% | Maxim Group | Jason McCarthy | $20 → $30 | Maintains | Buy | Get Alert |
| 03/19/2024 | ATNM | Buy Now | Actinium Pharma | $7.04 | 610.23% | HC Wainwright & Co. | Joseph Pantginis | $50 → $50 | Maintains | Buy | Get Alert |
| 03/11/2024 | ATNM | Buy Now | Actinium Pharma | $7.04 | 610.23% | HC Wainwright & Co. | Joseph Pantginis | $50 → $50 | Maintains | Buy | Get Alert |
| 12/11/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 127.27% | B. Riley Securities | Yuan Zhi | $20 → $16 | Maintains | Buy | Get Alert |
| 10/03/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 184.09% | B. Riley Securities | Yuan Zhi | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/07/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 610.23% | HC Wainwright & Co. | Joseph Pantginis | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 64.77% | HSBC | Morten Herholdt | → $11.6 | Initiates | → Buy | Get Alert |
| 08/15/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 610.23% | HC Wainwright & Co. | Joseph Pantginis | $53 → $50 | Maintains | Buy | Get Alert |
| 05/16/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 652.84% | HC Wainwright & Co. | Joseph Pantginis | → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/20/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 652.84% | HC Wainwright & Co. | Joseph Pantginis | → $53 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | — | William Blair | Andy Hsieh | — | Downgrade | Outperform → Market Perform | Get Alert |
| 02/21/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 652.84% | HC Wainwright & Co. | Joseph Pantginis | → $53 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | ATNM | Buy Now | Actinium Pharma | $7.04 | 652.84% | HC Wainwright & Co. | Joseph Pantginis | → $53 | Reiterates | → Buy | Get Alert |
| 10/31/2022 | ATNM | Buy Now | Actinium Pharma | $7.04 | 155.68% | B. Riley Securities | Yuan Zhi | $16 → $18 | Maintains | Buy | Get Alert |
| 10/31/2022 | ATNM | Buy Now | Actinium Pharma | $7.04 | 652.84% | HC Wainwright & Co. | Joseph Pantginis | $45 → $53 | Maintains | Buy | Get Alert |
| 09/08/2022 | ATNM | Buy Now | Actinium Pharma | $7.04 | 184.09% | Cantor Fitzgerald | Kristen Kluska | → $20 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Actinium Pharma (ATNM)?
The latest price target for Actinium Pharma (AMEX: ATNM) was reported by HC Wainwright & Co. on April 1, 2024. The analyst firm set a price target for $50.00 expecting ATNM to rise to within 12 months (a possible 610.23% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Actinium Pharma (ATNM)?
The latest analyst rating for Actinium Pharma (AMEX: ATNM) was provided by HC Wainwright & Co., and Actinium Pharma reiterated their buy rating.
When was the last upgrade for Actinium Pharma (ATNM)?
There is no last upgrade for Actinium Pharma.
When was the last downgrade for Actinium Pharma (ATNM)?
The last downgrade for Actinium Pharmaceuticals Inc happened on February 21, 2023 when William Blair changed their price target from N/A to N/A for Actinium Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Actinium Pharma (ATNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actinium Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actinium Pharma was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating Actinium Pharma (ATNM) correct?
While ratings are subjective and will change, the latest Actinium Pharma (ATNM) rating was a reiterated with a price target of $0.00 to $50.00. The current price Actinium Pharma (ATNM) is trading at is $7.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.